Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21571648 | 0.95 | PAICS (0.42) | PAICSKCNH2HDAC3HDAC2ATR | |
| SCHEMBL20352164 | 0.91 | PAICS (0.54) | PAICS | |
| SCHEMBL20339062 | 0.91 | PAICS (0.45) | PAICSKCNH2HDAC3HDAC2SMYD3 | |
| SCHEMBL24220529 | 0.89 | PAICS (0.49) | PAICSKCNH2HDAC3HDAC2CYP1A2 | |
| SCHEMBL21571660 | 0.87 | PAICS (0.45) | PAICSKCNH2HDAC3HDAC2SMYD3 | |
| SCHEMBL21571649 | 0.86 | PAICS (0.35) | PAICSKCNH2 | |
| SCHEMBL21571665 | 0.86 | PAICS (0.49) | PAICSKCNH2HDAC3HDAC2CYP1A2 | |
| SCHEMBL20352014 | 0.83 | PAICS (0.39) | PAICSKCNH2HDAC3HDAC2SMYD3 | |
| SCHEMBL21571640 | 0.82 | PAICS (0.42) | PAICS | |
| SCHEMBL20352073 | 0.82 | PAICS (0.41) | PAICSKCNH2HDAC3HDAC2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3562824-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| EP-3562824-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LifeArc (GB) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122549-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, CDK12, CDK13 | PAICS 1/4885KCNH2 2442/4885HDAC3 558/4885 |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, CDK13, CDK12 | PAICS 1/4885KCNH2 2703/4885HDAC3 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.